Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy
Somatic and Visceral Analgesic Efficacy and Opioid-Sparing Effect of Ultrasound-Guided Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy: A Randomized Controlled Trial
This prospective randomized controlled study will compare the postoperative analgesic efficacy and opioid-sparing effect of ultrasound-guided bilateral intertransverse process block (ITPB) with bilateral transversus abdominis plane (TAP) block combined with rectus sheath block in adults undergoing elective robotic or laparoscopic hepatectomy. A total of 64 participants will be randomly assigned in a 1:1 ratio to the ITPB group or the TAP block group. Both groups will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. The primary outcome is cumulative opioid consumption during the first 24 hours after surgery, expressed as intravenous morphine equivalents. Secondary outcomes include cumulative opioid consumption through 72 hours, incisional and visceral pain intensity, shoulder pain, sensory block distribution, rescue analgesic use, quality of recovery, postoperative recovery parameters, and adverse events.
調査の概要
状態
条件
詳細な説明
Eligible adults scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia will be screened according to the predefined inclusion and exclusion criteria. After written informed consent is obtained, participants will receive preoperative education regarding pain assessment and patient-controlled analgesia and will complete the baseline Quality of Recovery-15 assessment.
On the day of surgery, participants will be randomly assigned in a 1:1 ratio using a computer-generated randomization sequence with allocation concealed using sealed opaque envelopes.
Before induction of general anesthesia, the assigned regional block will be performed under mild sedation and real-time ultrasound guidance by an experienced anesthesiologist. Participants assigned to the ITPB group will receive bilateral intertransverse process block at the T6-7 and T9-10 levels. Participants assigned to the comparator group will receive bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block.
Both groups will receive 0.3% ropivacaine at four injection sites, with 15 mL administered at each site, for a total volume of 60 mL and a total dose of 180 mg. In participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.
Sensory block will be assessed using cold and pinprick testing at 5, 15, and 30 minutes after block placement. Participants, anesthesia and postoperative care providers, postoperative outcome assessors, and the statistical analyst will remain masked to treatment allocation. Because of the nature of the procedure, the anesthesiologist performing the assigned regional block cannot be masked and will not participate in subsequent postoperative management or outcome assessment.
All participants will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. Postoperative outcomes will be assessed at 2, 4, 6, 12, 24, 48, and 72 hours after surgery and at discharge as applicable.
Blood samples will be collected at 35 minutes, 60 minutes, 90 minutes, 2 hours, 6 hours, and 25 hours after completion of the regional block.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Bon-Nyeo Koo, Professor
- 電話番号:+82-10-6208-5797
- メール:KOOBN@yuhs.ac
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Adults aged 19 years or older. American Society of Anesthesiologists physical status I-III. Scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia.
Able to understand and use patient-controlled analgesia (PCA). Able to understand the purpose and procedures of the study and voluntarily provide written informed consent.
Exclusion Criteria:
History of allergy to local anesthetics or study medications. Coagulopathy, defined as INR > 1.5 or platelet count < 70,000/μL, or current anticoagulant use.
Infection at the regional block site. History of chronic pain or chronic opioid use for 3 months or longer. History of drug or alcohol abuse or dependence. Severe cardiopulmonary dysfunction or neurological disease. Cognitive impairment or psychiatric disease preventing cooperation with pain assessment, including the Numerical Rating Scale (NRS).
Body mass index (BMI) < 18 or > 35 kg/m². Pregnancy or breastfeeding. Scar at the block site that interferes with ultrasound visualization or local anesthetic spread.
History of abdominal surgery.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ITPB Group
Participants will receive ultrasound-guided bilateral intertransverse process block at the T6-7 and T9-10 levels before induction of general anesthesia. |
Before induction of general anesthesia and under mild sedation, bilateral intertransverse process block will be performed under real-time ultrasound guidance at the T6-7 and T9-10 levels. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.
他の名前:
|
|
アクティブコンパレータ:TAP + Rectus Sheath Block Group
Participants will receive ultrasound-guided bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block before induction of general anesthesia. |
Before induction of general anesthesia and under mild sedation, bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block will be performed under real-time ultrasound guidance. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cumulative Postoperative Opioid Consumption at 24 Hours
時間枠:From the end of surgery through 24 hours postoperatively
|
Cumulative opioid consumption during the first 24 hours after surgery will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents and summing the converted doses. |
From the end of surgery through 24 hours postoperatively
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cumulative Postoperative Opioid Consumption at Additional Time Points
時間枠:At 2, 4, 6, 12, 48, and 72 hours postoperatively.
|
Cumulative postoperative opioid consumption at each specified time point will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents. |
At 2, 4, 6, 12, 48, and 72 hours postoperatively.
|
|
Incisional Pain Intensity
時間枠:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
Incisional or somatic pain intensity will be assessed separately using the Numeric Rating Scale (NRS). |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Visceral Pain Intensity
時間枠:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
Deep or visceral abdominal pain intensity will be assessed separately using the Numeric Rating Scale (NRS). Participants will be instructed preoperatively to distinguish deep or generalized abdominal pain from pain at the incision site. |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Shoulder Pain Incidence and Intensity Assessed Using the Numeric Rating Scale (NRS)
時間枠:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
The presence of postoperative shoulder pain associated with diaphragmatic irritation will be recorded, and its intensity will be assessed using the Numeric Rating Scale (NRS). |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Extent and Distribution of Sensory Block
時間枠:At 5, 15, and 30 minutes after completion of the regional block.
|
Sensory block will be assessed using cold and pinprick testing. The highest and lowest blocked dermatomes, the total number of blocked dermatomes, anterior and posterior spread, and the presence or absence of posterior/paravertebral sensory block will be recorded. |
At 5, 15, and 30 minutes after completion of the regional block.
|
|
Pain Intensity at Rest and During Coughing or Movement
時間枠:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
Pain intensity at rest and during coughing or movement will be assessed using the Numeric Rating Scale (NRS). |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Time to First Rescue Analgesic Request
時間枠:Up to 72 hours after surgery.
|
Time to the first request for rescue analgesia will be recorded. |
Up to 72 hours after surgery.
|
|
Frequency of Rescue Analgesic Administration
時間枠:During the first 48 hours postoperatively.
|
The number of rescue analgesic administrations during the first 48 postoperative hours will be recorded. |
During the first 48 hours postoperatively.
|
|
Quality of Recovery-15 (QoR-15) Score
時間枠:On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).
|
Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire on postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21). |
On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).
|
|
Time to First Flatus
時間枠:From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).
|
The time to first postoperative flatus will be recorded. |
From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).
|
|
Time to First Ambulation
時間枠:From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).
|
The time to first postoperative ambulation will be recorded. |
From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).
|
|
Postoperative Length of Hospital Stay
時間枠:From surgery through hospital discharge, an expected average of approximately 8 days.
|
Postoperative length of hospital stay will be recorded as the number of calendar days from the date of surgery to hospital discharge. The date of surgery will be defined as postoperative day (POD) 0. |
From surgery through hospital discharge, an expected average of approximately 8 days.
|
|
Opioid-Related Adverse Events
時間枠:At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
The incidence of opioid-related adverse events, including nausea, vomiting, excessive sedation, respiratory depression, pruritus, urinary retention, and reduced gastrointestinal motility, will be assessed. |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Block-Related Complications
時間枠:From regional block placement through 72 hours postoperatively.
|
The incidence of block-related complications, including pneumothorax, pleural puncture, hematoma, infection, local anesthetic systemic toxicity, nerve injury, lower-limb weakness, unintended neuraxial block, and intra-abdominal organ injury, will be assessed. |
From regional block placement through 72 hours postoperatively.
|
|
Comprehensive Complication Index (CCI)
時間枠:At hospital discharge, an expected average of approximately 8 days after surgery.
|
Postoperative complications will be assessed using the Comprehensive Complication Index (CCI) through hospital discharge. |
At hospital discharge, an expected average of approximately 8 days after surgery.
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 4-2026-1244
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。